New Customer 5% Off

Copy a coupon code below and apply it when checkout

5%
OFF
New Customer 5% Off
No expiration date
-44.444444444444% PURE HEALTH-P021 Click to enlarge

PURE HEALTH-P021

$ 160.00

624sold

  • 💥💥Free shipping on orders of $1000 or more!
  • Get it between November 19 ~ November 24
  • Over 18 people have this in their carts right now
  • V*****u in New York, US United States bought this (2 Hours ago)

Total $ 160.00

Recent Orders
—
0
Name
Order
Quantity
Date
Trusted Store
99%Issue-Free
SecureCheckout
$10KID Protect

Payment Security

Privacy Protection

Efficient Shipping

Customer Support

product description

P21 (P021)
1. Basic Overview
P21, also known as P021, is a synthetic lipophilic peptide mimetic derived from the active domain of Ciliary Neurotrophic Factor (CNTF). It was developed by Dr. Khalid Iqbal’s research team for neurodegeneration research.
Amino Acid Sequence: Ac-DGGLAG-NH₂
Molecular Weight: 529.55 Da
CAS: No official universal CAS registry number (novel research peptide)
Form: Lyophilized white crystalline powder
Core Feature: Can cross the blood-brain barrier (BBB) in preclinical animal models. It replicates CNTF’s neuroprotective benefits without severe weight loss/cachexia side effects caused by full-length CNTF protein.
2. Mechanism of Action
Upregulate BDNF Production
Stimulates elevated Brain-Derived Neurotrophic Factor (BDNF) expression within the hippocampus. BDNF supports neuronal survival, dendritic spine growth and synaptic plasticity.
Inhibit GSK-3β Kinase
Suppresses activity of glycogen synthase kinase 3-beta. This reduces abnormal hyperphosphorylation of tau protein, one major hallmark neurofibrillary tangle pathology in Alzheimer’s disease.
Reduce Amyloid Beta Toxicity
Modulates APP processing, lowering the generation and aggregation of Aβ peptide in preclinical AD models.
Promote Hippocampal Neurogenesis
Supports the generation of new neurons in the dentate gyrus, a brain region critical for memory formation and learning.
Modulate CNTF/LIF Pathway
Selectively activates neurotrophic signaling while avoiding the LIF-mediated metabolic wasting effects associated with native CNTF.
3. Main Research Applications
Alzheimer’s disease & tauopathy preclinical animal models
Hippocampal neurogenesis, memory and cognitive function research
Synaptic plasticity and neuronal regeneration experiments
Neuroinflammation and neurodegeneration pathway studies
Traumatic brain injury (TBI) neuronal recovery models
Comparative research: P21 vs full-length CNTF; P21 combined with nootropic peptides
Age-related cognitive decline and brain senescence laboratory studies
4. Reconstitution Instructions (Lyophilized Vial)
Common specification: 5mg / 10mg per vial
Let peptide vial reach room temperature; disinfect rubber stopper with alcohol wipe.
Slowly inject Bacteriostatic Water along the inner glass wall. Avoid direct impact onto lyophilized powder.
Recommended mixing scheme: 10mg powder + 2mL BAC water → Concentration = 5 mg/mL
Gently rotate the vial to dissolve powder. DO NOT shake violently to prevent peptide structural degradation. Qualified solution is clear and colourless.
Storage Requirements
Unreconstituted lyophilized powder: Hermetically sealed, stored at -20°C, protected from light. Stable for up to 24 months.
Reconstituted peptide solution: Refrigerate 2°C ~ 8°C, stable within 28 days. Do not freeze reconstituted liquid; repeated freeze-thaw impairs activity.
5. Research Administration Protocols
Two common experimental routes in preclinical research: Subcutaneous injection & Intranasal delivery.
1) Subcutaneous Injection (Widely used)
Low starting tolerance dose: 100–250 mcg once daily
Standard experimental dose: 300–500 mcg once daily
High experimental dose: Up to 750 mcg once daily (limited long-term safety data)
Injection site: Lower abdomen or anterior thigh; rotate injection positions regularly.
2) Intranasal Administration (Preferred for CNS-targeted research)
Intranasal delivery bypasses systemic circulation and directly targets brain tissue.
Working concentration: 1–2 mg/mL reconstituted solution
Dosage reference: 50–200 mcg once daily via nasal instillation
Reference Experimental Cycle
Continuous administration for 6–12 weeks, followed by a minimum 4-week washout period before starting a new research cycle.
6. Precautions & Observed Adverse Reactions
Pure laboratory research compound. Not authorized for human therapeutic use.
Strict aseptic technique required during reconstitution to prevent microbial contamination.
Discard solution immediately if turbidity, precipitation or discoloration appears.
Within standard experimental doses, systemic adverse reactions are rare. Occasional mild transient redness may appear at subcutaneous injection sites.
Avoid concurrent use with other CNTF / neurotrophic mimetics unless specified by your research protocol.
No large-scale human clinical trial data exists. All results are limited to cell culture and rodent preclinical models.
Short Version (For Product Page / Customer Direct Message)
P21 (P021)
P21 (P021) is a BBB-permeable synthetic CNTF mimetic peptide. It elevates BDNF levels, inhibits GSK-3β, reduces tau hyperphosphorylation and promotes hippocampal neurogenesis. It is widely used in laboratory research focused on neurodegeneration, Alzheimer’s mechanisms, cognitive function and neuronal repair.
Reconstitution
Mix lyophilized powder with bacteriostatic water. Rotate gently; avoid violent shaking. Reconstituted solution must be refrigerated and used within 28 days.
Reference Research Dosage
Subcutaneous: 100–500 mcg once daily. Intranasal: 50–200 mcg once daily. Research cycles run 6–12 weeks with washout intervals.

Product NamePURE HEALTH-P021
Specification
Purity≥ 99%
FormLyophilized powder
StorageStore at -20°C in a cool, dry place

Reviews are currently unavailable.